Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
The GLP‑1 GIP co‑agonist pipeline is ushering in a new era of metabolic therapy that could reshape the way clinicians approach type 2 diabetes and obesity management. As drug developers push beyond single-pathway therapies like GLP‑1 receptor agonists, new combinations—such as GLP‑1/GIP dual agonists and triple agonists—are showing potential to …
Read More »Inside the GLP‑1/GIP Pipeline: What the Next Wave of Co‑Agonists Could Mean for Care
